Eli Lilly's Weight-Loss Pill Data Overshadows Sales Beat; Warner Bros. Discovery & Intel News

Eli Lilly's Weight-Loss Pill Setback

• 💡 Eli Lilly shares experienced a significant drop of approximately 14% despite a sales beat, due to disappointing data from its experimental weight-loss pill.
• 🎯 The pill achieved its primary goal of helping people lose weight, but the average weight loss of 11% fell short of Wall Street's expectation of 14-15%, which is comparable to existing GLP-1 injectable medicines.
• ⚠️ Gastrointestinal side effects were comparable to injectables, not the expected reduction, which is viewed as a negative for its commercial potential.
• 🚀 The pharmaceutical industry is exploring two main directions for obesity treatments: combination medicines and more convenient oral options like pills, which could be cheaper to manufacture and acquire.

Warner Bros. Discovery's Strategic Split

• 📺 Warner Bros. Discovery reported strong performance in its streaming and studio businesses, but its traditional TV networks continue to struggle, with a 25% slump in EBITDA.
• 🧩 The company plans to split into two separate entities by mid-2026, separating low-growth TV assets from higher-growth streaming and studio businesses to unlock shareholder value.
• 🎬 The studio business showed a strong forward slate, including a DC reboot, aiming for $3 billion in studio EBITDA and currently holding a significant share of the domestic box office.

Peloton's Profitability Push Amidst Stagnant Growth

• 📊 Peloton is focusing on cost-cutting and profitability, with outstanding progress in adjusted EBITDA, significantly exceeding guidance.
• 📉 Despite strong financial metrics, the company faces challenges in reinvigorating demand and subscriber growth, with a recent 6% workforce reduction.
• 💰 Future strategies may involve increasing subscription prices rather than focusing on volume growth for a sustainable go-forward plan.

Intel CEO Faces Scrutiny

• ⚠️ President Trump called for the resignation of Intel CEO Pat Gelsinger, citing conflicts of interest related to his minority investments in Chinese companies.
• 🧐 While the Intel board reportedly defended Gelsinger, the allegations, highlighted by Senator Tom Cotton, raise questions about his ties to Chinese entities.
• 🔄 If Gelsinger were to step down, it could reignite discussions about breaking up Intel and potentially selling off parts of the company, impacting its foundry and chip design strategy.